葛酮通络胶囊联合沙库巴曲缬沙坦治疗心力衰竭患者的效果

Effects of Getong Tongluo capsules combined with Sacubitril/Valsartan in treatment of patients with heart failure

目的:观察葛酮通络胶囊联合沙库巴曲缬沙坦治疗心力衰竭患者的效果。方法:选取2020年9月至2022年5月该院收治的80例心力衰竭患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各40例。两组均进行基础治疗,在此基础上,对照组予以沙库巴曲缬沙坦治疗,观察组在对照组基础上联合葛酮通络胶囊治疗,两组均连续治疗2个月。比较两组临床疗效,治疗前后心功能指标[左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)]水平、炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)]水平、心肌纤维化指标[转化生长因子-β1(TGF-β1)、结缔组织生长因子(CTGF)]水平,以及不良反应发生率。结果:观察组治疗总有效率为95.00%(38/40),高于对照组的77.50%(31/40),差异有统计学意义(P<0.05);观察组LVEF水平高于对照组,LVESV、LVEDV、LVESD、LVEDD水平均低于对照组,差异有统计学意义(P<0.05);观察组IL-6、TNF-α、CTGF、TGF-β1水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:葛酮通络胶囊联合沙库巴曲缬沙坦治疗心力衰竭患者可提高治疗总有效率,改善心功能指标和心肌纤维化指标水平,减轻炎症反应,效果优于单纯沙库巴曲缬沙坦治疗。

Objective:To observe effects of Getong Tongluo capsules combined with Sacubitril/Valsartan in the treatment of patients with heart failure.Methods:A prospective study was conducted on 80 patients with heart failure admitted to this hospital from September 2020 to May 2022.They were divided into control group and observation group according to the random number table method,40 cases in each group.Both groups received basic treatment.On this basis,the control group was treated with Sacubitril/Valsartan,while the observation group was treated with Getong Tongluo capsules on the basis of that of the control group.Both groups were treated continuously for 2 months.The clinical efficacy,the levels of cardiac function indexes[left ventricular end-systolic volume(LVESV),left ventricular end-diastolic volume(LVEDV),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF)],the inflammatory factor levels[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)],the myocardial fibrosis index levels[transforming growth factor-β1(TGF-β1),connective tissue growth factor(CTGF)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 95.00%(38/40),which was higher than 77.50%(31/40)in the control group,and the difference was statistically significant(P<0.05).The level of LVEF in the observation group was higher than that in the control group,the levels of LVESV,LVEDV,LVESD and LVEDD were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of IL-6,TNF-α,CTGF and TGF-β1 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Getong Tongluo capsules combined with Sacubitril/Valsartan in the treatment of the patients with heart failure can improve the total effective rate of treatment,improve the cardiac function and the myocardial fibrosis,and reduce the inflammatory reactions.Moreover,it is superior to single Sacubitril/Valsartan treatment.